Multicentric Castleman's disease in HIV infection: A systematic review of the literature

AIDS Reviews

Volumn 10, Issue 1, 2008, Pages 25-35

  Mylona, Eleni E ^a   Baraboutis, Ioannis G ^a   Lekakis, Lazaros J ^b   Georgiou, Ourania ^a   Papastamopoulos, Vasilios ^a   Skoutelis, Athanasios ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Highly active antiretroviral therapy; HIV; Multicentric Castleman's disease

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BLEOMYCIN; C REACTIVE PROTEIN; CHLORAMBUCIL; CIDOFOVIR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; IMMUNOMODULATING AGENT; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CD4+ T LYMPHOCYTE; CYTOPENIA; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENDOCRINE DISEASE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGAMMAGLOBULINEMIA; HYPOALBUMINEMIA; INCIDENCE; KAPOSI SARCOMA; LABORATORY TEST; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MULTIPLE ORGAN FAILURE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; POEMS SYNDROME; POLYNEUROPATHY; PROGNOSIS; PROTEIN BLOOD LEVEL; REMISSION; RESPIRATORY TRACT DISEASE; REVIEW; SEX DIFFERENCE; SPLENECTOMY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GIANT LYMPH NODE HYPERPLASIA; HIV INFECTIONS; HUMANS;

EID: 42149172420     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Collins L, Fowler A, Tong C, de Ruiter A. Multicentric Castleman's disease in HIV infection. Int J STD AIDS. 2006;17:19-25.
2. Waterston A, Bower M. Fifty years of Multicentric Castlemans disease. Acta Onoologica. 2004;43:699-704.
3. Peterson B, Frizzera G. Multicentric Castleman's disease. Semin Oncol. 1993;20:636-47.
4. Du M, Liu H, Diss T, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naïve B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97:2130-6.
5. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman's disease with anti-CD20 monoclonal antibody therapy. Blood. 2001;98:3473-5.
6. Lachant N, Sun N, Leong L, Oseas R, Prince H. Multicentric angiofollicular lymph node hyperplasia (Castlemans disease) followed by Kaposis sarcoma in two homosexual males with AIDS. J Clin Pathol. 1985;83:27-33.
7. Lowenthal D, Filippa D, Richardson M, Bertoni M, Straus D. Generalized lymphadenopathy with morphologic features of Castleman's disease in an HIV-positive man. Cancer. 1987;60:2454-8.
8. Wynia M, Shapiro B, Kuvin J, Skolnik P. Fatal Castleman's disease and pulmonary Kaposi's sarcoma in an HIV-seropositive woman. AIDS. 1995;9:814-6.
9. Oksenhendler E, Duane M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10:61-7.
10. Lanzafame M, Carretta G, Trevenzoli M, Lazzarini L, Concia S. Successful treatment of Castleman's disease with HAART in two HIV-infected patients. J Infect. 2000;40:90-1.
11. Scott D, Cabral L, Harrington W. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol. 2001;66:148-51.
12. Marrache F, Larroche C, Mémain N, et al. Prolonged remission of HIV-associated multicentric Castleman's disease with an anti-CD20 monoclonal antibody as primary therapy. AIDS. 2003;17:1409-19.
13. Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard J. Human herpesvirus 8-positive Castleman disease in HIV-infected patients: The impact of HAART. Clin Infect Dis. 2002;35:880-2.
14. Aoki y, Tosato G, Fonville T, Pittaluga S. Serum viral IL-6 in AIDS-related multicentric Castleman disease. Blood. 2001;97:2526-7.
15. Liberopoulos E, Tolis C, Bai M. Efremidis S, Pavlidis N, Elisaf M. Successful treatment of HIV-related Castleman's disease: A case report and literature review. Oncology. 2003;65:182-6.
16. Hillier J, Shaw P, Miller R, et al. Imaging features of multicentric Castleman's disease in HIV infection. Clin Radiol. 2004;59:596-601.
17. Jung C, Emmerich B, Goebel F, Bogner J. Successful treatment of a patient with HIV-associated multicentric Castleman disease with thalidomide. Am J Hematol. 2004;75:176-8.
18. Casper C, Nichols W, Huang M, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. 2004;103:1632-4.
19. Loi S, Goldstein D, Clezy K, Milliken S, Hoy J, Chipman M. Castleman's disease and HIV infection in Australia. HIV Med. 2004;5:157-62.
20. Bacon C, Miller R, Noursadeghi M, Mcnamara C, Du M, Dogan A. Pathology of bone marrow in HHV-8-associated multicentric Castleman disease. Br J Haematol. 2004;127:585-91.
21. Neuville S, Agbalika F, Rabian C, Briére J, Molina J. Failure of rituximab in HIV-associated multicentric Castleman disease. Am J Hematol. 2005;79:337-9.
22. Kotb R, Vincent I, Dulioust A, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Heamatol. 2006;76:269-71.
23. Fowler A, Collins L, de Ruiter A, Whittaker S, Kulasegaram R, Bradbeer C. Multicentric Castleman's disease in a patient with HIV. Int J STD AIDS. 2006;17:63-4.
24. Nord J, Karter D. Low dose IFNα therapy for HIV-associated multicentric Castleman's disease. Int J STD AIDS. 2003;14:61-2.
25. Casquero A, Barroso A, Guerrero M, Górgolas M. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol. 2006;85:185-7.
26. Bouvresse S, Marcelin A, Franck N, et al. The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient. AIDS. 2007;21:1492-3.
27. Kumari P, Schechter G, Saini N, Benator D. Successful treatment of HIV-related Castleman's disease with IFNα. Clin Inf Dis. 2000; 31:602-4.
28. Izuchukwu I, Tourbaf K, Mahoney M. An unusual presentation of Castleman's disease: a case report. BMC Infect Dis. 2003;3:20.
29. Newsom-Davis T, Bower M, Wildfire A, et al. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNFα levels. Leuk Lymphoma. 2004; 45:1939-41.
30. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128:657-62.
31. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-IL-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627-32.
32. Weisenburger D, Nathwani B, Winberg C, Rapparport H. Multicentric angiofollicular lymph node hyperplasia: A clinicopathologic study of 16 cases. Hum Pathol. 1985;16:162-72.
33. Ascoli V, Signoretti S, Onetti-Muda A, et al. Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. J Pathol. 2001;193:200-9.
34. Frizzera G, Massarelli G, Banks PM, Rosai J. A systematic lymphoproliferative disorder with morphologic features of Castleman's disease. Am J Surg Pathol. 1983;7:211-31.
35. Do K, Lee J, Seo J, et al. Pulmonary parenchymal involvement of low-grade lymphoproliferative disorders. J Comput Assist Tomogr. 2005;29:825-30.
36. Guihot A, Couderc L, Agbalika F, et al. Pulmonary manifestations of multicentric Castleman's disease in HIV infection: a clinical, biological and radiological study. Eur Resp J. 2005;26:118-25.
37. Belec L, Mohamed A, Authier F, et al. Human herpes-virus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Blood. 1999;93:3643-53.
38. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpes virus-like DNA sequence in AIDS associated Kaposi's sarcoma. Science. 1994;266:1865.
39. Parravicini C, Chandran B, Corbellino M. Differential viral protein expression in KS-associated herpesvirus infected diseases: KS, primary effusion lymphoma and multicentric Castleman's disease. Am J Pathol. 2000;156:743-9.
40. Dupin N, Diss T, Kellam P, et al. HHV8 is associated with a plasmablastic variant of Castleman's disease that is linked to HHV8 positive plasmablasitc lymphoma. Blood. 2000;95:1406-12.
41. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-relate non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99:2331-6.
42. Marcelin A, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood. 2003;102:2786-8.
43. Beck J, Hsu S, Wijdenes J, et al. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-IL-6 antibody. N Engl J Med. 1994;330:602-5.
44. Hess G, Wagner V, Kreft A, Heussel C, Huber C. Effects of bortezomib on proinflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol. 2006;134:544-5.
45. Löw P, Neipel F, Rascu A, et al. Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. Eur J Med Res. 1998;3:461-4.
46. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. HAART prolongs time to treatment failure in Kaposi's sarcoma AIDS. 1999;13:2105-11.
47. Zietz C, Bogner J, Goebel F, Lohrs U. An unusual cluster of cases in Castleman's disease during HAART for AIDS. N Engl J Med. 1999;340:1923-4.